Lenacapavir disruption in ARV market
Gilead issued voluntary licenses for lenacapavir (PrEP). While management sees 5+ year timeline to access markets, analyst questioned whether Laurus will secure license without sterile fill-finish capabilities.
LAURUSLABS / Q2-FY25 / risks
Keep the risk register visible.
Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Recurring timing of shipment excuses
Analyst pointed out that timing of shipment issues have been cited for 2-3 consecutive quarters to explain API declines. Management deflected by claiming September quarter had higher revenue recognition, but underlying pattern suggests structural issues.
Elevated working capital and debt levels
Operating cash flow negligible in H1; net debt at INR 2,679 crore with Debt/EBITDA at 3.4x. Lumpy Q4-centric revenue pattern means working capital deterioration will recur annually.
LSPL plant regulatory status
Small LSPL plant (acquired May 2020) received US FDA five observations in December 2023. While import alert has been lifted, recovery timeline remains unclear. Investor questioned why same standards aren't applied to acquired facilities.